Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in Oman is increasing steadily due to various factors.
Customer preferences: Customers in Oman have shown a preference for personalized medicine, which is tailored to the individual's genetic makeup and specific cancer type. This has led to an increase in demand for targeted therapies and immunotherapies. Additionally, patients are increasingly seeking out drugs that have fewer side effects and are more effective in treating their specific cancer type.
Trends in the market: The oncology drugs market in Oman is witnessing a shift towards more innovative therapies, such as immunotherapies and targeted therapies. This is due to the increasing prevalence of cancer in the country and the need for more effective treatments. The market is also seeing an increase in the number of biosimilars, which are cheaper versions of existing biologic drugs. This is due to the government's efforts to reduce healthcare costs and increase access to affordable treatments.
Local special circumstances: Oman has a high prevalence of non-communicable diseases, including cancer. This has led to an increase in demand for oncology drugs in the country. Additionally, the government has implemented various initiatives to improve cancer care, such as the National Oncology Centre and the Oman Cancer Association. These initiatives have increased awareness about cancer and the importance of early detection and treatment.
Underlying macroeconomic factors: The Omani government has been investing heavily in the healthcare sector, which has led to an increase in the availability of healthcare services and facilities. This has also led to an increase in the demand for oncology drugs. Additionally, the country's growing population and aging demographic are contributing to the increasing demand for cancer treatments. The government's efforts to diversify the economy and reduce dependence on oil are also expected to contribute to the growth of the oncology drugs market in Oman.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
